#1 Clinical Trials Search in Europe

Bevacizumab

Bevacizumab, a recombinant humanized monoclonal antibody, has been the subject of numerous clinical trials exploring its potential in treating various medical conditions. This article examines the use of bevacizumab in clinical trials for conditions ranging from eye disorders to cancer and even COVID-19. We’ll look at how this drug works, its administration methods, and the outcomes researchers are studying to determine its effectiveness and safety.

Table of Contents

What is Bevacizumab?

Bevacizumab is a medication used in the treatment of various types of cancer. It is known by the brand name Avastin[3]. Bevacizumab belongs to a class of drugs called monoclonal antibodies, which are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as cancer cells[4].

What Conditions Does Bevacizumab Treat?

Bevacizumab is used to treat several types of cancer, including:

  • Metastatic Colorectal Cancer (mCRC): This is cancer that has spread from the colon or rectum to other parts of the body[1].
  • Advanced or Metastatic Hepatocellular Carcinoma (HCC): This is a type of liver cancer that has either advanced locally or spread to other parts of the body[5].
  • Glioblastoma: This is an aggressive type of cancer that occurs in the brain or spinal cord[2].
  • Choroidal Neovascularisation: This is a condition where new blood vessels grow in the choroid layer of the eye, often associated with age-related macular degeneration[6].

How Does Bevacizumab Work?

Bevacizumab is an anti-angiogenic agent, which means it works by blocking the formation of new blood vessels. Specifically, it targets and inhibits a protein called vascular endothelial growth factor (VEGF). VEGF is responsible for stimulating the growth of new blood vessels, a process called angiogenesis[2].

In cancer, tumors need a blood supply to grow and spread. By blocking VEGF, Bevacizumab helps to cut off the blood supply to tumors, potentially slowing or stopping their growth[1].

How is Bevacizumab Administered?

Bevacizumab is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency of administration can vary depending on the type of cancer being treated and other factors. Here’s a general example of how it might be given:

  • Initial dose: 5 mg/kg given as an intravenous (IV) infusion over 90 minutes
  • Second dose: If the first dose is well-tolerated, 5 mg/kg IV over 60 minutes
  • Subsequent doses: If well-tolerated, 5 mg/kg IV over 30 minutes

Doses are typically given every 2 or 3 weeks, depending on the treatment plan[1].

Bevacizumab in Combination Therapies

Bevacizumab is often used in combination with other cancer treatments to enhance effectiveness. Some common combination therapies include:

  • FOLFOXIRI plus Bevacizumab: This combination includes the drugs fluorouracil, leucovorin, oxaliplatin, and irinotecan along with Bevacizumab. It’s used in the treatment of metastatic colorectal cancer[4].
  • Atezolizumab and Bevacizumab: This combination is used in the treatment of hepatocellular carcinoma (liver cancer)[5].
  • Chemotherapy plus Bevacizumab: Various chemotherapy regimens may be combined with Bevacizumab depending on the type and stage of cancer[1].

Ongoing Clinical Trials

Several clinical trials are currently underway to further investigate the effectiveness of Bevacizumab in various cancer treatments. These trials are exploring:

  • The use of Bevacizumab in different stages of colorectal cancer[7]
  • Combination therapies with Bevacizumab for liver cancer[5]
  • The effectiveness of Bevacizumab in treating glioblastoma (brain cancer)[2]
  • The use of Bevacizumab in eye conditions like choroidal neovascularisation[6]

Potential Side Effects

Like all medications, Bevacizumab can cause side effects. Some potential side effects include:

  • High blood pressure
  • Bleeding or blood clotting problems
  • Slow wound healing
  • Gastrointestinal perforations (holes in the stomach or intestines)
  • Kidney problems
  • Fatigue
  • Diarrhea
  • Decreased appetite

It’s important to discuss potential side effects with your healthcare provider. They will monitor you closely during treatment and can help manage any side effects that occur[1][8].

Aspect Details
Drug Name Bevacizumab (also known as Avastin, Zeribev)
Drug Type Recombinant humanized monoclonal antibody
Mechanism of Action Targets vascular endothelial growth factor (VEGF), inhibiting blood vessel growth and activation
Conditions Studied Various cancers, eye disorders (AMD, DME), COVID-19 pneumonia
Administration Methods Intravitreal injection (eye disorders), intravenous infusion (cancer, COVID-19)
Primary Outcomes Measured Visual acuity, retinal thickness, tumor response, survival rates, oxygen levels
Safety Monitoring Adverse events, eye-related complications, systemic effects
Dosage Range Varies by condition (e.g., 1.25mg/0.05mL for eye injections, 3-7.5mg/kg for intravenous use)
Trial Phases Phase 1 to Phase 3, depending on the specific study

FAQ

  • What is bevacizumab and how does it work? Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It works by preventing VEGF from binding to its natural receptor, which inhibits the growth and activation of blood vessels. This mechanism makes it potentially useful in treating conditions involving abnormal blood vessel growth or increased vascular permeability.
  • In which medical conditions is bevacizumab being studied? Bevacizumab is being studied in a wide range of conditions, including various types of cancer (rectal, lung, ovarian, cervical, and glioblastoma), eye disorders such as age-related macular degeneration and diabetic macular edema, and even in severe cases of COVID-19 pneumonia.
  • How is bevacizumab administered in these clinical trials? The administration of bevacizumab varies depending on the condition being treated. For eye disorders, it's typically given as an intravitreal injection directly into the eye. For cancer treatments, it's usually administered intravenously. In COVID-19 studies, it's given as an intravenous infusion.
  • What are some of the primary outcomes researchers are looking at in these trials? Researchers are examining various outcomes, including visual acuity and retinal thickness for eye disorders, tumor response and survival rates for cancer, and improvements in oxygen levels and reduced need for ventilation in COVID-19 patients. They're also closely monitoring safety and potential side effects across all trials.
  • Are there any potential side effects or risks associated with bevacizumab use? While the specific side effects can vary depending on the condition being treated and the method of administration, researchers are monitoring for potential adverse events in all trials. These may include eye-related complications for intravitreal injections, or systemic effects such as changes in blood pressure or increased risk of bleeding for intravenous administration.

Ongoing Clinical Trials on Bevacizumab

  • Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +9

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

  • Testing GSK5764227 combined with standard cancer treatments in patients with advanced solid tumors to evaluate safety and effectiveness

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of FOLFOX or FOLFIRI chemotherapy with fruquintinib or bevacizumab as second-line treatment for patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • Treatment with trastuzumab deruxtecan, capecitabine and bevacizumab for patients with HER2-positive metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • A study of pumitamig and ipilimumab in patients with advanced or unresectable liver cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +2

  • A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

    Recruiting

    4 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +5

Glossary

  • Bevacizumab: A recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), used in the treatment of various cancers and eye disorders.
  • Vascular Endothelial Growth Factor (VEGF): A protein that stimulates the formation of blood vessels. It plays a crucial role in the growth of tumors and the development of certain eye conditions.
  • Intravitreal injection: A procedure where medication is injected directly into the vitreous cavity of the eye, commonly used in the treatment of retinal disorders.
  • Macular Edema: A condition where fluid accumulates in the macula, the central part of the retina, leading to vision problems.
  • Age-related Macular Degeneration (AMD): An eye disease that causes vision loss in the center of the field of vision, typically in older adults.
  • Optical Coherence Tomography (OCT): A non-invasive imaging technique that uses light waves to take cross-section pictures of the retina.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Acute Respiratory Distress Syndrome (ARDS): A severe lung condition characterized by rapid onset of widespread inflammation in the lungs, often seen in critically ill patients.
  • Contrast Sensitivity: The ability to distinguish between finer and finer increments of light versus dark, an important measure of visual function.
  • Pterygium: A growth of pink, fleshy tissue on the conjunctiva, the clear tissue that lines the eyelids and covers the eyeball.

References

  1. https://clinicaltrials.gov/study/NCT01878422
  2. https://clinicaltrials.gov/study/NCT01836536
  3. https://clinicaltrials.gov/study/NCT04126044
  4. https://clinicaltrials.gov/study/NCT01163396
  5. https://clinicaltrials.gov/study/NCT05665348
  6. https://clinicaltrials.gov/study/NCT00344617
  7. https://clinicaltrials.gov/study/NCT02339116
  8. https://clinicaltrials.gov/study/NCT02271464